Literature DB >> 25977336

NKX3.1 Suppresses TMPRSS2-ERG Gene Rearrangement and Mediates Repair of Androgen Receptor-Induced DNA Damage.

Cai Bowen1, Tian Zheng2, Edward P Gelmann3.   

Abstract

TMPRSS2 gene rearrangements occur at DNA breaks formed during androgen receptor-mediated transcription and activate expression of ETS transcription factors at the early stages of more than half of prostate cancers. NKX3.1, a prostate tumor suppressor that accelerates the DNA repair response, binds to androgen receptor at the ERG gene breakpoint and inhibits both the juxtaposition of the TMPRSS2 and ERG gene loci and also their recombination. NKX3.1 acts by accelerating DNA repair after androgen-induced transcriptional activation. NKX3.1 influences the recruitment of proteins that promote homology-directed DNA repair. Loss of NKX3.1 favors recruitment to the ERG gene breakpoint of proteins that promote error-prone nonhomologous end-joining. Analysis of prostate cancer tissues showed that the presence of a TMPRSS2-ERG rearrangement was highly correlated with lower levels of NKX3.1 expression consistent with the role of NKX3.1 as a suppressor of the pathogenic gene rearrangement. ©2015 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25977336      PMCID: PMC4511965          DOI: 10.1158/0008-5472.CAN-14-3387

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  55 in total

1.  Roles for Nkx3.1 in prostate development and cancer.

Authors:  R Bhatia-Gaur; A A Donjacour; P J Sciavolino; M Kim; N Desai; P Young; C R Norton; T Gridley; R D Cardiff; G R Cunha; C Abate-Shen; M M Shen
Journal:  Genes Dev       Date:  1999-04-15       Impact factor: 11.361

2.  Punctuated evolution of prostate cancer genomes.

Authors:  Sylvan C Baca; Davide Prandi; Michael S Lawrence; Juan Miguel Mosquera; Alessandro Romanel; Yotam Drier; Kyung Park; Naoki Kitabayashi; Theresa Y MacDonald; Mahmoud Ghandi; Eliezer Van Allen; Gregory V Kryukov; Andrea Sboner; Jean-Philippe Theurillat; T David Soong; Elizabeth Nickerson; Daniel Auclair; Ashutosh Tewari; Himisha Beltran; Robert C Onofrio; Gunther Boysen; Candace Guiducci; Christopher E Barbieri; Kristian Cibulskis; Andrey Sivachenko; Scott L Carter; Gordon Saksena; Douglas Voet; Alex H Ramos; Wendy Winckler; Michelle Cipicchio; Kristin Ardlie; Philip W Kantoff; Michael F Berger; Stacey B Gabriel; Todd R Golub; Matthew Meyerson; Eric S Lander; Olivier Elemento; Gad Getz; Francesca Demichelis; Mark A Rubin; Levi A Garraway
Journal:  Cell       Date:  2013-04-25       Impact factor: 41.582

3.  Decreased NKX3.1 protein expression in focal prostatic atrophy, prostatic intraepithelial neoplasia, and adenocarcinoma: association with gleason score and chromosome 8p deletion.

Authors:  Carlise R Bethel; Dennis Faith; Xiang Li; Bin Guan; Jessica L Hicks; Fusheng Lan; Robert B Jenkins; Charles J Bieberich; Angelo M De Marzo
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

4.  Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression.

Authors:  C Bowen; L Bubendorf; H J Voeller; R Slack; N Willi; G Sauter; T C Gasser; P Koivisto; E E Lack; J Kononen; O P Kallioniemi; E P Gelmann
Journal:  Cancer Res       Date:  2000-11-01       Impact factor: 12.701

5.  13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.

Authors:  Peter C Albertsen; James A Hanley; David F Penson; George Barrows; Judith Fine
Journal:  J Urol       Date:  2007-03       Impact factor: 7.450

6.  XRCC1 coordinates the initial and late stages of DNA abasic site repair through protein-protein interactions.

Authors:  A E Vidal; S Boiteux; I D Hickson; J P Radicella
Journal:  EMBO J       Date:  2001-11-15       Impact factor: 11.598

7.  TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis.

Authors:  Outi R Saramäki; Anna E Harjula; Paula M Martikainen; Robert L Vessella; Teuvo L J Tammela; Tapio Visakorpi
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

8.  NKX3.1 activates expression of insulin-like growth factor binding protein-3 to mediate insulin-like growth factor-I signaling and cell proliferation.

Authors:  Erin Muhlbradt; Ekaterina Asatiani; Elizabeth Ortner; Antai Wang; Edward P Gelmann
Journal:  Cancer Res       Date:  2009-03-03       Impact factor: 12.701

9.  Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer.

Authors:  Rajesh Thangapazham; Francisco Saenz; Shilpa Katta; Ahmed A Mohamed; Shyh-Han Tan; Gyorgy Petrovics; Shiv Srivastava; Albert Dobi
Journal:  BMC Cancer       Date:  2014-01-13       Impact factor: 4.430

10.  A constitutional translocation t(1;17)(p36.2;q11.2) in a neuroblastoma patient disrupts the human NBPF1 and ACCN1 genes.

Authors:  Karl Vandepoele; Vanessa Andries; Nadine Van Roy; Katrien Staes; Jo Vandesompele; Geneviève Laureys; Els De Smet; Geert Berx; Frank Speleman; Frans van Roy
Journal:  PLoS One       Date:  2008-05-21       Impact factor: 3.240

View more
  17 in total

Review 1.  Peptide-Based Therapeutics for Oncology.

Authors:  Elizaveta Fisher; Kirill Pavlenko; Alexander Vlasov; Galina Ramenskaya
Journal:  Pharmaceut Med       Date:  2019-02

2.  CRISPR/Cas9-Mediated Point Mutation in Nkx3.1 Prolongs Protein Half-Life and Reverses Effects Nkx3.1 Allelic Loss.

Authors:  Cai Bowen; Maho Shibata; Hailan Zhang; Sarah K Bergren; Michael M Shen; Edward P Gelmann
Journal:  Cancer Res       Date:  2020-09-17       Impact factor: 12.701

Review 3.  Genetically Engineered Mouse Models of Prostate Cancer in the Postgenomic Era.

Authors:  Juan M Arriaga; Cory Abate-Shen
Journal:  Cold Spring Harb Perspect Med       Date:  2019-02-01       Impact factor: 6.915

4.  Loss of PTEN Accelerates NKX3.1 Degradation to Promote Prostate Cancer Progression.

Authors:  Cai Bowen; Michael C Ostrowski; Gustavo Leone; Edward P Gelmann
Journal:  Cancer Res       Date:  2019-06-18       Impact factor: 12.701

5.  Patient-specific Boolean models of signalling networks guide personalised treatments.

Authors:  Julio Saez-Rodriguez; Laurence Calzone; Arnau Montagud; Jonas Béal; Luis Tobalina; Pauline Traynard; Vigneshwari Subramanian; Bence Szalai; Róbert Alföldi; László Puskás; Alfonso Valencia; Emmanuel Barillot
Journal:  Elife       Date:  2022-02-15       Impact factor: 8.713

Review 6.  Linking DNA Damage and Hormone Signaling Pathways in Cancer.

Authors:  Matthew J Schiewer; Karen E Knudsen
Journal:  Trends Endocrinol Metab       Date:  2016-03-01       Impact factor: 12.015

7.  NKX3-1 Is a Useful Immunohistochemical Marker of EWSR1-NFATC2 Sarcoma and Mesenchymal Chondrosarcoma.

Authors:  Ken-Ichi Yoshida; Isidro Machado; Toru Motoi; Antonina Parafioriti; Maribel Lacambra; Hitoshi Ichikawa; Akira Kawai; Cristina R Antonescu; Akihiko Yoshida
Journal:  Am J Surg Pathol       Date:  2020-06       Impact factor: 6.394

8.  NK3 homeobox 1 (NKX3.1) up-regulates forkhead box O1 expression in hepatocellular carcinoma and thereby suppresses tumor proliferation and invasion.

Authors:  Jingyi Jiang; Zheng Liu; Chao Ge; Cong Chen; Fangyu Zhao; Hong Li; Taoyang Chen; Ming Yao; Jinjun Li
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

9.  Transcriptional regulation of the Nkx3.1 gene in prostate luminal stem cell specification and cancer initiation via its 3' genomic region.

Authors:  Qing Xie; Zhu A Wang
Journal:  J Biol Chem       Date:  2017-07-05       Impact factor: 5.157

10.  Nkx3.1 controls the DNA repair response in the mouse prostate.

Authors:  Hailan Zhang; Tian Zheng; Chee Wai Chua; Michael Shen; Edward P Gelmann
Journal:  Prostate       Date:  2015-12-10       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.